IMM 1.45% 34.0¢ immutep limited

Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC, page-18

  1. 6 Posts.
    lightbulb Created with Sketch. 7
    Wilson’s describe results ‘as expected’ and reiterate .91c medium SP target.
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.